MedTrace Logo

Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer

NCT00841113 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 177

Last updated 2009-02-11

No results posted yet for this study

Summary

To compare the safety of efficacy of abarelix versus goserelin plus bicalutamide in patients with advanced or metastatic prostate cancer.

Conditions

Interventions

DRUG

Abarelix

100 mg by Intramuscular injection on days; 1, 15 and 29 and monthly thereafter

DRUG

Goserelin plus Bicalutamide

Goserelin - 3.6 mg by monthly subcutaneous injection Biaclutamide 50 mg orally daily for first three months

Sponsors & Collaborators

  • Speciality European Pharma Limited

    lead INDUSTRY

Principal Investigators

  • Frans M J Debruyne, MD · University Hospital Nijmegen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-01-31
Primary Completion
2001-02-28
Completion
2003-02-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00841113 on ClinicalTrials.gov